A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Phase 1 Completed 46 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.

Timeline

Start: 2021-04-14
Primary completion: 2022-02-27
Completion: 2022-02-27

Publications

Soleman SI, Maya J, Levesque P, Mohammad A, Christopher L, Schumacher J, Nanduri A, Sivakumar P, Kozinn M, Costet P, Wang C, Richter J, Hawthorne D, Bui A, Rao VS, Dickerson D, Testani J, Ramirez-Valle F, Baribaud F, Murthy B, Merali S. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor. Clin Pharmacol Ther. 2024 Dec;116(6):1627-1634. doi: 10.1002/cpt.3430. Epub 2024 Sep 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986308	Unknown	1 mg	Oral
Subject	BMS-986308	Unknown	3 mg	Oral
Subject	BMS-986308	Unknown	10 mg	Oral
Subject	BMS-986308	Unknown	30 mg	Oral
Subject	BMS-986308	Unknown	100 mg	Oral
Subject	Furosemide	Other / unclassified	—	—

Indications

No indication recorded.